{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:39:22Z","timestamp":1770813562242,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.msard.2025.106665","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T22:57:43Z","timestamp":1754521063000},"page":"106665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Treatment of First and Subsequent Attacks in Multiple Sclerosis"],"prefix":"10.1016","volume":"101","author":[{"given":"Christopher H","family":"Hawkes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2025.106665_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.58.1.31","article-title":"A randomized, double-blind, placebo-controlled MRI study of anti\u2013herpes virus therapy in MS","volume":"58","author":"Bech","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106665_bib0002","first-page":"581","volume":"326","author":"Beck","year":"1992"},{"issue":"6578","key":"10.1016\/j.msard.2025.106665_bib0003","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.msard.2025.106665_bib0004","first-page":"160","article-title":"Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nature Rev. Neurol"},{"issue":"Supplement_1","key":"10.1016\/j.msard.2025.106665_bib0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clinical Infect. Dis"},{"key":"10.1016\/j.msard.2025.106665_bib0006","doi-asserted-by":"crossref","unstructured":"Georgopoulou E.M., Palkopoulou M., Liakopoulos D., Kerazi E., Kalaentzis A.M., Barmparoussi V., Kokkinos M., Kaliontzoglou A., Anagnostouli M. Myelin oligodendrocyte glycoprotein antibody disease (MOGAD)-monophasic optic neuritis and Epstein-Barr virus (EBV): a case report of rare comorbid diagnoses in an adolescent from a remote Greek island. Cureus. 2024 Sep 8;16(9):e68946. doi: 10.7759\/cureus.68946. PMID: 39381468; PMCID: PMC11461040.","DOI":"10.7759\/cureus.68946"},{"issue":"2","key":"10.1016\/j.msard.2025.106665_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192109","article-title":"Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells","volume":"13","author":"Hassani","year":"2018","journal-title":"PloS one"},{"key":"10.1016\/j.msard.2025.106665_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106403","article-title":"Is multiple sclerosis a microgliopathy?","volume":"96","author":"Hawkes","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.msard.2025.106665_bib0009","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0404.2005.00516.x","article-title":"Presence of Epstein\u2013Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity","volume":"112","author":"H\u00f6llsberg","year":"2005","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106665_bib0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40263-024-01153-5","article-title":"Repurposing licensed drugs with activity against Epstein\u2013Barr virus for treatment of multiple sclerosis: a systematic approach","volume":"39","author":"Li","year":"2025","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.msard.2025.106665_bib0011","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/24.6.947","article-title":"Acyclovir concentrations in serum and cerebrospinal fluid at steady state","volume":"24","author":"Lycke","year":"1989","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.msard.2025.106665_bib0012","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF00868517","article-title":"Acyclovir treatment of relapsing-remitting multiple sclerosis: a randomized, placebo-controlled, double-blind study","volume":"243","author":"Lycke","year":"1996","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106665_bib0013","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1128\/AAC.47.8.2438-2441.2003","article-title":"Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir","volume":"47","author":"Lycke","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.msard.2025.106665_bib0014","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0404.1997.tb00210.x","article-title":"Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis","volume":"95","author":"Martin","year":"1997","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.msard.2025.106665_bib0015","first-page":"727","article-title":"Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up","volume":"65","year":"2008","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106665_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2019-321653","article-title":"Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence","volume":"91","author":"Petzold","year":"2020","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.msard.2025.106665_bib23","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1128\/AAC.01023-10","article-title":"Valacyclovir for herpes simplex encephalitis","volume":"55","author":"Pouplin","year":"2011","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"3","key":"10.1016\/j.msard.2025.106665_bib0017","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.msard.2025.106665_bib0018","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1177\/11206721241230567","article-title":"New insights in the pathogenic mechanism of multiple sclerosis: is Epstein-Barr virus associated with optic nerve involvement?","volume":"34","author":"Remol\u00ed-Sargues","year":"2024","journal-title":"Eur J Ophthalmol"},{"issue":"9","key":"10.1016\/j.msard.2025.106665_bib0020","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1007\/s00415-024-12571-2","article-title":"Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis optica spectrum disorder","volume":"271","author":"Shi","year":"2024","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.msard.2025.106665_bib0021","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1128\/AAC.00729-09","article-title":"Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function","volume":"54","author":"Smith","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.msard.2025.106665_bib0022","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/biomedicines10010192","article-title":"Neuroprotective effects of novel treatments on acute optic neuritis-A meta-analysis","volume":"10","author":"Tsai","year":"2022","journal-title":"Biomedicines"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:43:55Z","timestamp":1755650635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"alternative-id":["S2211034825004079"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106665","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of First and Subsequent Attacks in Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106665"}}